Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Cancer Prev Res (Phila). 2023 May 1;16(5):247–258. doi: 10.1158/1940-6207.CAPR-23-0004

Figure 5. Changes in immune cell markers observed in PCLS with iloprost treatment.

Figure 5.

Cell types were characterized by Vectra Polaris assay. (A) Percent of total cells labeled as CD45+, T cells, macrophages, and B cells for each mouse group. (B) Normalized cell density of T cells, macrophages, and B cells. (C) Percent of cell types among CD45+ cells from each mouse group. (n=1) WT, wild type; Fzd9−/−, Fzd9 knockout; ILO, iloprost.